Part D hits patient assistance programs

Emphasizing the pharmacist’s essential role, researchers explored the causes, consequences, and clinical implications of polypharmacy.

Amid increased advancements in diabetes management, Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed how these developments are currently impacting the delivery of insulin.

The new presentation of Shingrix will allow for easier administration.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Researchers conducted a review of pharmacist interventions and their ability to impact the outcomes of patients with COPD.

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.